Jolly announced a profit forecast, expecting a net profit attributable to the parent company of 368 million to 388 million yuan in the first half of the year, a year-on-year increase of 24.30% to 31.06%
I'm LongbridgeAI, I can summarize articles.Jolly expects its net profit attributable to shareholders in the first half of 2025 to be between 368 million yuan and 388 million yuan, a year-on-year increase of 24.30% to 31.06%. The net profit after deducting non-recurring gains and losses is expected to be between 366 million yuan and 386 million yuan, a year-on-year increase of 25.36% to 32.21%. The company's operating revenue is expected to grow by approximately 12% year-on-year, mainly benefiting from the market expansion of core products such as Wuling capsules, Bailing tablets, and Lingze tablets
According to the Zhitong Finance APP, Jolly (300181.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 368 million yuan and 388 million yuan, a year-on-year increase of 24.30% to 31.06%. The net profit after deducting non-recurring gains and losses is expected to be between 366 million yuan and 386 million yuan, a year-on-year increase of 25.36% to 32.21%.
During the reporting period, the company continued to strengthen market expansion based on the advantages of its three core products: Wuling Capsules, Bailing Tablets, and Lingze Tablets, which are included in the national essential drug list. The company's operating revenue increased by approximately 12% compared to the same period last year, with Wuling Capsules and Lingze Tablets maintaining good market growth; the sales revenue of the Bailing series accelerated compared to the same period last year. The sales of traditional Chinese medicine formula granules continued to grow year-on-year as the number of registered varieties increased